OPEN END-TURBO-OPTIONSSCHEIN - NOVO NORDISK ADR B | Market Closed - BOERSE MUENCHEN 20:37:01 02/07/2024 BST | ||
| 12.9 EUR | -4.02% |
|
| Current month | -0.62% | ||
| 1 month | +14.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 02/07/24 | 12.9 | -4.02% |
| 01/07/24 | 13.44 | +3.54% |
| 28/06/24 | 12.98 | -1.96% |
| 27/06/24 | 13.24 | +0.46% |
| 26/06/24 | 13.18 | -3.80% |
Real-time BOERSE MUENCHEN
Last update July 02, 2024 at 08:37 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | HSBC |
| WKN | HG844P |
| ISIN | DE000HG844P5 |
| Date issued | 06/02/2023 |
| Strike | 73.94 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.49 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.93 € |
|---|---|
| Lowest since issue | 0.47 € |
| Spread | 0.06 € |
| Spread % | 0.46% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- Certificat
